Drug Profile
E 10A
Alternative Names: Ad5-E10A; E10ALatest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator Guangzhou Double Bioproducts
- Developer Guangzhou Double Bioproducts; Sun Yat-Sen University
- Class Antineoplastics; Eye disorder therapies; Gene therapies
- Mechanism of Action Endostatin replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Squamous cell cancer
Most Recent Events
- 11 Oct 2021 No development reported - Phase-II for Squamous cell cancer (Combination therapy) in China (Intratumoural)
- 11 Oct 2018 E 10A is still in phase III trials for Squamous cell cancer (Combination therapy, Metastatic disease, Late-stage disease) in China (Intratumoural)
- 10 Oct 2018 No recent reports on development identified - phase III for Squamous cell cancer (Combination therapy, Metastatic disease, Late-stage disease) in China (Intratumoural)